Montelukast Zentiva

Montelukast, the active ingredient in Montelukast Zentiva, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma, allergic rhinitis, and to prevent exercise‑induced bronchospasm in adults and children. GNH USA supplies Montelukast Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory and allergic conditions. - Asthma: provides maintenance therapy that reduces airway inflammation and frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. - Exercise‑induced bronchospasm: prevents bronchoconstriction triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Mood changes, including suicidal thoughts

When prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: safety not established; weigh benefits against potential risks. - Breastfeeding: unknown excretion; consider risk to infant. - Liver impairment: use with caution and monitor hepatic function. - Concomitant enzyme‑inducing drugs (e.g., phenobarbital, rifampin) may lower effectiveness. - Not for acute asthma attacks: intended for maintenance therapy only. - Store at room temperature: keep in original container, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital, carbamazepine, rifampin: can markedly decrease montelukast plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise drug levels and risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect; monitor INR. - Theophylline: may require level checks. - Beta‑agonists: additive bronchodilator effect; observe clinical response.